Shopping Cart
- Remove All
- Your shopping cart is currently empty
Nicodicosapent is a fatty acid niacin conjugate and an inhibitor of the sterol regulatory element-binding protein (SREBP), which is a key regulator of cholesterol metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase, and NPC1L1.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
2 mg | $94 | 5 days | |
25 mg | $690 | 6-8 weeks | |
50 mg | $897 | 6-8 weeks | |
100 mg | $1,490 | 6-8 weeks |
Description | Nicodicosapent is a fatty acid niacin conjugate and an inhibitor of the sterol regulatory element-binding protein (SREBP), which is a key regulator of cholesterol metabolism proteins such as PCSK9, HMG-CoA reductase, ATP citrate lyase, and NPC1L1. |
In vitro | Nicodicosapent obviously suppresses ApoB secretion in a dose-dependent manner (IC50: 27 μM). Nicodicosapent displays a synergistic inhibition on secreted PCSK9 ( IC50: 17 μM). Nicodicosapent reduces the production of mature SREBP-2 protein in HepG2 cells but does not interact with the GPR109A receptor. Nicodicosapent causes time-dependent hydrolysis in HepG2 cells. |
In vivo | Nicodicosapent (100 mg/kg p.o.) produces high plasma levels of nicotinic acid in the plasma. ApoE*3-Leiden mice treated with Nicodicosapent display an obvious reduction in PCSK9 levels, LDL particles including VLDL and LDL cholesterol, and plasma triglycerides. |
Molecular Weight | 449.63 |
Formula | C28H39N3O2 |
Cas No. | 1269181-69-2 |
Relative Density. | 1.013 g/cm3 (Predicted) |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 100 mg/mL (222.41 mM) | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.